Birch Hill Investment Advisors LLC Purchases 4,664 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Birch Hill Investment Advisors LLC grew its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 172,821 shares of the pharmaceutical company’s stock after purchasing an additional 4,664 shares during the period. Vertex Pharmaceuticals makes up 3.2% of Birch Hill Investment Advisors LLC’s portfolio, making the stock its 10th biggest position. Birch Hill Investment Advisors LLC owned about 0.07% of Vertex Pharmaceuticals worth $69,595,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of VRTX. State Street Corp grew its position in Vertex Pharmaceuticals by 0.8% during the third quarter. State Street Corp now owns 11,816,249 shares of the pharmaceutical company’s stock valued at $5,495,501,000 after purchasing an additional 90,173 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of Vertex Pharmaceuticals by 18.1% during the third quarter. Jennison Associates LLC now owns 5,550,386 shares of the pharmaceutical company’s stock worth $2,581,373,000 after acquiring an additional 851,054 shares in the last quarter. Wellington Management Group LLP boosted its position in Vertex Pharmaceuticals by 17.2% during the third quarter. Wellington Management Group LLP now owns 4,798,870 shares of the pharmaceutical company’s stock valued at $2,231,858,000 after purchasing an additional 704,421 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in Vertex Pharmaceuticals by 5.8% in the third quarter. Massachusetts Financial Services Co. MA now owns 2,905,705 shares of the pharmaceutical company’s stock valued at $1,351,385,000 after purchasing an additional 159,693 shares in the last quarter. Finally, Janus Henderson Group PLC increased its position in Vertex Pharmaceuticals by 4.1% in the 3rd quarter. Janus Henderson Group PLC now owns 2,516,831 shares of the pharmaceutical company’s stock worth $1,170,506,000 after purchasing an additional 100,114 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on VRTX. Cantor Fitzgerald reissued an “overweight” rating and issued a $480.00 price target on shares of Vertex Pharmaceuticals in a research note on Friday, January 31st. Piper Sandler decreased their target price on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating for the company in a research report on Monday, January 27th. Canaccord Genuity Group raised their price target on shares of Vertex Pharmaceuticals from $361.00 to $408.00 and gave the company a “sell” rating in a report on Wednesday, November 6th. Jefferies Financial Group upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price objective for the stock from $500.00 to $550.00 in a report on Monday, December 9th. Finally, Citigroup assumed coverage on Vertex Pharmaceuticals in a research report on Thursday, November 14th. They issued a “buy” rating and a $575.00 price target for the company. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $502.58.

Vertex Pharmaceuticals Trading Down 2.5 %

Shares of NASDAQ VRTX opened at $469.32 on Friday. The stock has a market cap of $120.86 billion, a price-to-earnings ratio of -235.84, a P/E/G ratio of 1.80 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. The company’s fifty day moving average is $435.87 and its 200-day moving average is $462.68.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.